Abnormal activation of NF‐κB and MAPK signaling pathways affect osimertinib resistance and influence the recruitment of myeloid‐derived suppressor cells to shape the immunosuppressive tumor immune microenvironment

BACKGROUND: Osimertinib is the first‐line treatment for patients with epidermal growth factor receptor (EGFR) mutations, but the treatment options after drug resistance are limited. Previous studies have suggested that EGFR is in an immunosuppressive tumor immune microenvironment (TIME). However, th...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chao, Fei, Kailun, Liu, Lihui, Duan, Jianchun, Wang, Zhijie, Li, Sini, Xu, Jiachen, Zhang, Xue, Tian, Yanhua, Qu, Yan, Bai, Hua, Wang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10317600/
https://www.ncbi.nlm.nih.gov/pubmed/37221702
http://dx.doi.org/10.1111/1759-7714.14929

Ejemplares similares

Ejemplares similares